Table 3. Odds ratios for the component associations that comprise the antibody-mediated pathway: 1) HPV-16 antibody status with smoking status, and 2) HPV-16 antibody status with HPV-16 infection status stratified by never, former, and current smokers; first among the full population, then after restricting to five or more lifetime sexual partners.

	Never		Former		Current
	OR	95% CI	OR	95% CI	OR	95% CI
Full study population
1) Positive antibody status with smoking status^a	1.0	ref	0.76	(0.54, 1.08)	0.52	(0.40, 0.68)
2) Antibody status with infection, stratified by smoking^b
negative	1.0	ref	1.0	ref	1.0	ref
positive	1.03	(0.60, 1.78)	0.22	(0.03, 1.79)	0.18	(0.04, 0.75)
Among women with five or more lifetime sexual partners
1) Positive antibody status with smoking status^a	1.0	ref	0.72	(0.48, 1.10)	0.52	(0.39, 0.71)
2) Antibody status with infection, stratified by smoking^b
negative	1.0	ref	1.0	ref	1.0	ref
positive	0.81	(0.36, 1.80)	0.32	(0.04, 2.68)	0.10	(0.01, 0.72)

all models adjusted for model covariates: age, age at sexual debut, and lifetime number of sexual partners

the stratification by smoking status is due to a significant interaction term between smoking and antibodies (P = 0.015);

negative antibody status is the referent group for each smoking category